Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Secures First-Round Patent Win For Tecfidera; One More To Go

Executive Summary

PTAB rejected an inter partes review challenge to a key patent protecting the oral multiple sclerosis blockbuster to 2028 in the US, but another challenge remains outstanding.

You may also be interested in...



Biogen Makes Lifecycle Gambit In Next-Gen MS Drug Deal With Alkermes

ALKS 8700 could help Biogen extend its MS franchise beyond Tecfidera. The next-generation fumarate may have better GI tolerability and patent protection into 2033.

Biogen Staying "Laser-Focused" On Neuroscience

The company is under pressure from investors to add new pipeline assets, but stronger than expected initial sales of Spinraza helped to assuage near-term growth concerns.

Acorda Defeats Kyle Bass, Now Awaits Ruling In Ampyra ANDA Litigation

Patent Trial and Appeal Board upheld validity of four Acorda patents; district court judge to issue decision on five patents. Victory would block generic competition until 2025.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132553

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel